<DOC>
	<DOCNO>NCT00642304</DOCNO>
	<brief_summary>This single arm study ass efficacy safety subcutaneous C.E.R.A . administer maintenance hemoglobin level participant chronic renal anemia , dialysis . Participants currently receive maintenance treatment subcutaneous darbepoetin alfa epoetin beta receive monthly injection C.E.R.A. , start dose ( 120 , 200 300 microgram [ mcg ] subcutaneously [ SC ] ) derive dose darbepoetin alfa epoetin beta receive week precede study start .</brief_summary>
	<brief_title>A Study Subcutaneous C.E.R.A . Maintenance Hemoglobin Levels Participants With Chronic Renal Anemia Not Dialysis .</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Chronic renal anemia Stable darbepoetin alfa epoetin beta therapy past 8 week Transfusion red blood cell previous 8 week Poorly control hypertension require interruption epoetin treatment previous 6 month Acute chronic bleed require therapy within previous 8 week</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>